Stereotaxis, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
March 04, 2024 at 04:06 pm EST
Share
Stereotaxis, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 4.57 million compared to USD 7.3 million a year ago. Net loss was USD 5.04 million compared to USD 4.15 million a year ago. Basic loss per share from continuing operations was USD 0.07 compared to USD 0.06 a year ago. Diluted loss per share from continuing operations was USD 0.07 compared to USD 0.06 a year ago.
For the full year, revenue was USD 26.77 million compared to USD 28.15 million a year ago. Net loss was USD 20.71 million compared to USD 18.29 million a year ago. Basic loss per share from continuing operations was USD 0.27 compared to USD 0.26 a year ago. Diluted loss per share from continuing operations was USD 0.27 compared to USD 0.26 a year ago.
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation, fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Companyâs primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites.